CureVac granted patent for its manufacturing process to produce RNA

CureVac, a biopharmaceutical maker focused on mRNA-based drugs, was granted a patent by the U.S. Patent and Trademark Office for its manufacturing process for producing RNA. The company said it is the first in its field to get a patent for the entire manufacturing process of in vitro transcribed RNA. The patent covers processes for the in vitro transcription of template DNA including proprietary quality control steps for producing purified RNA. The company's technology works by delivering antigen-encoding mRNA molecules to the body to induce both cellular and humoral immune responses.